Dr. David Minor has contributed to 3 publications.
Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma.
Ascierto, P. A.,Minor, D.,Ribas, A.,Lebbe, C.,O'Hagan, A.,Arya, N.,Guckert, M.,Schadendorf, D.,Kefford, R. F.,Grob, J. J.,Hamid, O.,Amaravadi, R.,Simeone, E.,Wilhelm, ...; J. Clin. Oncol.. 2013 Sep 10.
See more >>
Lymphocytic vasculitis of the uterus in a patient with melanoma receiving ipilimumab.
Minor, D. R.,Bunker, S. R.,Doyle, J.; J. Clin. Oncol.. 2013 Jul 10.
See more >>
Inoperable bulky melanoma responds to neoadjuvant therapy with vemurafenib.
Fadaki, N., Cardona-Huerta, S., Martineau, L., Thummala, S., Cheng, S. T., Bunker, S. R., Garcia-Kennedy, R., Wang, W., Minor, D., Kashani-Sabet, M., Leong, S. P.; BMJ Case Rep. 2012.
See more >>